Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene
Main Category: Lung Cancer Also Included In: Cancer / Oncology ; Regulatory Affairs / Drug Approvals Article Date: 26 Aug 2011 - 17:00 PDT The US FDA has approved Xalkori for the treatment of late-stage NSCLC in patients who have the abnormal ALK gene.
Join the discussion below, or Read more at Medical News Today.
Since: Dec 05
#1 Aug 31, 2011
With the lastest press release from Pfizer about their new drug Xalkori, the queston of whether to consider spending $3,000 or more for a cell-based functional profiling test gets more interesting. The drug will cost $9,600 per patient per month and the gene test for it will cost $1,500 per patient. A biotech executive states the real cost of the drug is $9,600 plus 25 ALK tests, because that's how many patients will need to be screened for one to actually get Xalkori.
There are lots of things which determine if drugs work, beyond the existence of a given target (like ALK). Does the drug even get into the cancer cell? Does it get pumped out of the cell? Does the cell have ways of escaping drug effects? Can cells repair damage caused by the drug? Do combinations of drugs work in ways which can't be predicted on the basis of static gene expression patterns?
Tumor biology is a lot more complex than we'd like it to be. Cancer is more complex than its gene signature. Many common forms of cancer present as a host of mutated cells, each with a host of mutations. And they're genetically unstable, constantly changing. That's why so many cancers relapse after initially successful treatment. You kill off the tumor cells that can be killed off, but that may just give the ones that are left a free reign.
The idea of searching for clinical responders by testing for a single gene mutation seems like a nice theoretical idea, but you may have to test for dozens of protein expressions that may be involved in determining sensitivity/resistance to a given drug. Because if you miss just one, that might be the one which continues cancer growth. And at $1,500 a pop, that's a lot of dough, on top of the inflated price of the single drug!
The key to understanding the genome is understanding how cells work. The ultimate driver is "functional" pre-testing (is the cell being killed regardless of the mechanism) as opposed to "target" pre-testing (does the cell express a particular target that the drug is supposed to be attacking). While a "target" test tells you whether or not to give "one" drug, a "functional" pre-test can find other compounds and combinations and can recommend them, all from the one test.
Tel Aviv, Israel
#2 Nov 3, 2013
Hello can some one can advice me where can i buy some Xalkori(Crizotinib)?
Add your comments below
|Depression common after serious illness or medi...||Aug 3||Jaimie||6|
|Wilmot Cancer Institute welcomes two physicians||Aug '15||Dr Lewek||2|
|Genomic fingerprint may predict aggressive pros...||Jul '15||Spotted Girl||1|
|New Drug Shows Potential for Blood Cancer||Jun '15||Johnwillton||2|
|$20M cancer center opens today in Clifton Park||Jun '15||Dennis S||1|
|Researchers hail new cancer treatment that unlo...||Jun '15||Hypothetical||1|
|CTCA Oncologist Discusses Cancer Risks Among Mi...||May '15||Ms Louisiana||1|
Find what you want!
Search Oncology Forum Now
Copyright © 2015 Topix LLC